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Purpose: We describe a case of anterior necrotising scleritis secondary to Gemcitabine and Carboplatin
chemotherapy agents in a patient with metastatic breast cancer, which has not been previously reported.
Observations: A 50-year-old lady with recurrent metastatic breast cancer presented with unilateral
subconjunctival haemorrhage secondary to severe thrombocytopenia eight days following palliative
chemotherapy in the form of Gemcitabine and Carboplatin. Twelve days following the initial presenta-
tion, the subconjunctival haemorrhage had resolved, however there was evidence of anterior necrotising
scleritis with anterior chamber reaction and hypotony with choroidal effusion. This resolved with three
days of intravenous Methylprednisolone along with topical steroids and the area of necrosis remained
stable.
Conclusions and importance: Due to the chronological order of events, we infer a Gemcitabine and
Carboplatin-induced anterior necrotising scleritis, which has not been previously reported.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
We describe here a case of anterior necrotising scleritis sec-
ondary to combination of Gemcitabine and Carboplatin chemo-
therapy, which following extensive literature search has not been
previously reported.2. Case report
A 50-year old lady with recurrent breast cancer (ER/PR/HER-2
negative) and brain, supraclavicular, mediastinal and lung metas-
tases presented with one-day history of right eye subconjunctival
haemorrhage and epistaxis. She had Gemcitabine (1786 mg) and
Carboplatin (400 mg) as part of palliative chemotherapy eight days
previously. The patient was formally also admitted with pancyto-
penia and haemo-dynamically unstable epistaxis eight days
following Gemcitabine and Carboplatin chemotherapy and subse-
quently had the doses reduced.
When this patient was diagnosed with right breast carcinoma,
she had a mastectomy, axillary node clearance and completed six
cycles of Fluorouracil, Epirubicin hydrochloride and Cyclophos-
phamide chemotherapy combination with Neulasta cover. She did
not have life-threatening side effects during this period..K. Makuloluwa).
Inc. This is an open access article uOn the current presentation, BCVA was OD 6/36 and OS 6/12.
Patient had a known visual ﬁeld defect secondary to the brain
metastases. On examination, there was a dense right subcon-
junctival haemorrhage and associated proptosis with mild restric-
tion of ocular movements in all gazes. Examination of cornea, pupil
and fundus were unremarkable. The patient was diagnosed with
extensive subconjunctival haemorrhage and epistaxis secondary to
severe thrombocytopenia of 5  109/L, and she was referred to the
medical team for management of the global pancytopenia.
On day 4, she developed lid oedema and was treated with
intravenous Tazocin with Teicoplanin for probable pre-septal
cellulitis. Orbital cellulitis and metastases were ruled out with CT
and MRI scans respectively.
On day 6, both pre-septal component and subconjunctival
haemorrhage improved. However, patient developed corneal
oedema and anterior chamber cells with ﬁbrin and posterior syn-
echiae. Treatment was started as hourly prednisolone 1%, two-
hourly Exocin and once-a-day atropine 1% eye drops with lubri-
cants. The patient continued on 8 mg Dexamethasone orally as part
of her chemotherapy regime.
On day 12, there were signs of anterior necrotising scleritis,
measuring 10  10 mm nasally at limbus with persistent corneal
oedema, anterior chamber ﬁbrin and choroidal effusion (kissing
choroidals) with intra-ocular pressure (IOP) of 0 mmHg (Fig. 1).
Intravenous Methylprednisolone 1 g for three days was initiated in
addition to the above treatment. Following two doses ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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choroidal effusion resolved.
By day 15, right eye vision improved to 6/60 from hand move-
ments. Cornea was clearer and did not show signs of anterior
chamber reaction or ﬁbrin with the area of necrosis remaining
stable. The disc and macula remained healthy.
Since the above chemotherapy regime was poorly tolerated
regardless of the partial response, it was discontinued and changed
to oral Vinorelbine along with 8 mg oral Dexamethasone by her
oncology team. At present, right eye vision is 6/60 and the eye is
quiet. There is an area of deep pigmentation nasally with
conjunctival loss representing the necrotising scleritis. Topically,
the patient continues on prednisolone 1% eye drops twice per day
along with lubricants.3. Discussion
Extensive database search did not reveal any reported cases of
anterior necrotising scleritis secondary to Gemcitabine and Car-
boplatin chemotherapy regime.
Globally, breast cancer remains the commonest cancer affecting
the female population. Gemcitabine and platinum agents have
synergistic effects as described below by their mechanisms of ac-
tion. Both Gemcitabine and Carboplatin potentiate myelosup-
pression, including thrombocytopenia and that due to Carboplatin
is both dose-, and exposure-dependent.1,2
Gemcitabine is a deoxycytidine nucleoside analogue, which is
phosphorylated once entering the cell to active metabolites,
namely gemcitabine diphosphate and triphosphate.1 The latter
compound acts as a fraudulent base and integrates with DNA
instead of deoxycytidine triphosphate (dCTP).1 This results in
cessation of DNA synthesis secondary to masked chain termina-
tion.1 The gemcitabine diphosphate metabolite inactivates ribo-
nucleotide reductase which catalyses dCTP.1 Reduction in dCTP
potentiates gemcitabine phosphorylation and integration of gem-
citabine triphosphate with DNA, hence preserving the active me-
tabolites in tumour cells.1
Carboplatin is a cisplatin analogue, which interacts with water
molecules once entering the cell.2 Carboplatin forms intrastrand
adducts and interstrand cross-links via covalent bonds with
nucleophilic sites on guanine and adenine purines.2 These adducts
impede DNA transcription and replication resulting in miscoding
and breaks in DNA.2 Henceforth, apoptosis is induced viaFig. 1. Nasal aspect of sclera representing the anterior necrotising scleritis.regulators, such as p532. Consequently, there is an increased de-
mand for DNA repair molecules such as dCTPs, production of which
is inhibited by gemcitabine as described above.2
A review of the role of platinum agents in breast cancer has
stated that carboplatin was associated with an acute hypersensi-
tivity reaction usually with repeated exposure, which in turn may
permit ‘immune reconstitution’’.2 This may explain the inﬂamma-
tory process described in our patient as an anterior necrotising
scleritis, which rapidly responded to immunosuppression. We
ruled out other causes of infectious and non-infectious causes of
anterior scleritis with the use of blood tests. Our patient’s ACE
levels were low, which may be secondary to steroid therapy, whilst
urate levels were just above the normal range, which was likely to
be secondary to chemotherapy. She tested negative for ANCA,
Rheumatoid factor, Syphilis IgG and IgM. Although screening for
ANA’s showed a homogenous staining pattern with positive anti-
bodies to Ro, antibodies to dsDNA, La, Sm tested negative. Although
the patient was not tested for herpes simplex and herpes zoster
viruses, given that the inﬂammatory process settled with steroids
without the use of antivirals insinuate them as an unlikely culprit.
Previously it has been noted that especially in scleritis associated
with seropositive connective tissue disorders, capillaries become
under-perfused and eventually obstructed by thrombi with sus-
tained inﬂammation leading to areas of avascular tissue.3 However,
our patient is unlikely to have had avascular necrotising scleritis,
again because of immediate response to the immunosuppression as
well as insufﬁcient immunology screening result to suggest an
underlying seropositive disease.
There have been previous reports of drug-induced scleritis,
largely secondary to bisphosphonate use. A case series reported
intravenous pamidronate-induced unilateral scleritis, 16 of 17
which were anterior and one of which was posterior scleritis.4 They
postulated that cytokines released from a discrete class of T cells
inhibiting bone resorption resulted in an immunological reaction.4
Drug discontinuation led to resolution of scleritis.4 Another case
series showed scleritis associated with alendronate 5 Two patients
developed posterior scleritis and lid oedema with or without
myositis ten days and three weeks following alendronate therapy
respectively.5 There was a dramatic improvement with steroids.5
One patient developed anterior nodular scleritis and lid oedema
ﬁve months after alendronate therapy and this resolved with
diclofenac, a non-steroidal anti-inﬂammatory agent.5 Alendronate
was implicated due to the temporal relationship with the ocular
manifestations and was discontinued.5 Furthermore, there has
been a reported case of symmetrical polyarthropathy, orbital
myositis and posterior scleritis ten days following administration of
1993 Fluvirin vaccine.6 There was signiﬁcant resolution of symp-
toms with 40 mg of oral prednisolone.6 The authors implicated the
ﬂu vaccine due to the sequential association of symptoms and
suggested possible formation of immune complexes in type III
hypersensitivity as the underlying process.64. Conclusions
Due to the chronological order of events with an immediate
response to immunosuppression, we infer a Carboplatin, and
possibly Gemcitabine-induced anterior necrotising scleritis.5. Patient consent
The patient consented orally to the publication of this case
report.
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